https://pharmadevicenews.com/frontiers-fmc-376-triggered-responses-after-kras-inhibitor-failure-but-can-its-dual-state-mechanism-prevent-resistance/ PharmaDeviceNews en 2026-10-25T13:48:27+00:00 Frontier’s FMC-376 triggered responses after KRAS inhibitor failure, but can its dual-state mechanism prevent resistance? Adagrasib, European Society for Medical Oncology, FMC-376, Frontier Medicines, Keytruda, KRAS G12C, KRAZATI, LUMAKRAS, Marcelo Negrao, MD Anderson Cancer Center, pembrolizumab, PROSPER, sotorasib https://pharmadevicenews.com/wp-content/uploads/2026/06/Guardant360-CDx-FDA-approval-strengthens-the-liquid-biopsy-case-in-HER2-mutant-lung-cancer-e1781185177103.webp https://pharmadevicenews.com/beone-medicines-reports-new-phase-1-results-across-three-liver-and-lung-cancer-programmes/ PharmaDeviceNews en 2026-10-25T13:45:30+00:00 BeOne Medicines reports new Phase 1 results across three liver and lung cancer programmes BeOne Medicines, BG-C477, BGB-58067, BGB-B2033, European Society for Medical Oncology, KANDELA-302, Tevimbra, tislelizumab https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-17-2026-09_15_56-AM-e1789616803290.webp https://pharmadevicenews.com/catalyms-visugromab-lifted-bladder-cancer-complete-responses-to-33-but-can-it-help-patients-avoid-surgery/ PharmaDeviceNews en 2026-10-25T07:03:16+00:00 CatalYm’s visugromab lifted bladder cancer complete responses to 33%, but can it help patients avoid surgery? Andrea Necchi, CatalYm, European Society for Medical Oncology, GDFATHER-NEO, IRCCS San Raffaele Hospital, Keytruda, Nature Medicine, nivolumab, Opdivo, PADCEV, visugromab https://pharmadevicenews.com/wp-content/uploads/2026/03/Signatera-MRD-data-at-ASCO-GU-raises-new-questions-about-who-really-needs-cystectomy-e1772373660512.webp https://pharmadevicenews.com/genmab-and-incyte-are-combining-three-attacks-on-kras-mutant-colorectal-cancer-but-can-they-overcome-egfr-resistance/ PharmaDeviceNews en 2026-10-25T06:58:10+00:00 Genmab and Incyte are combining three attacks on KRAS-mutant colorectal cancer, but can they overcome EGFR resistance? DAWN-303, EGFR, GEN1158, Genmab, INCB161734, Incyte, KRAS G12D, LGR5, petosemtamab, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/07/Verastem-doses-first-patient-in-TARGET-D-203-Phase-2-colorectal-cancer-trial-e1785297624822.webp https://pharmadevicenews.com/bayer-reports-58-lower-metastasis-or-death-risk-with-nubeqa-in-phase-3-prostate-cancer-trial/ PharmaDeviceNews en 2026-10-25T06:33:14+00:00 Bayer reports 58% lower metastasis or death risk with NUBEQA in Phase 3 prostate cancer trial ARAMIS, ARANOTE, ARASENS, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Canadian Cancer Trials Group, darolutamide, DASL-HiCaP, European Society for Medical Oncology, NUBEQA, Orion Corporation, University of Sydney https://pharmadevicenews.com/wp-content/uploads/2026/06/AstraZenecas-Truqap-approval-raises-the-stakes-in-PTEN-deficient-prostate-cancer-care-e1781439693814.webp https://pharmadevicenews.com/astrazenecas-bladder-cancer-combination-cut-death-risk-by-42-but-can-it-compete-with-an-approved-rival-regimen/ PharmaDeviceNews en 2026-10-25T06:28:13+00:00 AstraZeneca’s bladder cancer combination cut death risk by 42%, but can it compete with an approved rival regimen? AstraZeneca, durvalumab, enfortumab vedotin, Imfinzi, KEYNOTE-905, Keytruda, Merck, New England Journal of Medicine, NIAGARA, PADCEV, United States Food and Drug Administration, VOLGA https://pharmadevicenews.com/wp-content/uploads/2026/05/Veracyte-enters-the-MRD-market-with-Medicare-backing-but-evidence-depth-will-decide-scale-e1778904337443.webp https://pharmadevicenews.com/astrazeneca-and-amgen-report-58-lower-death-risk-with-imfinzi-and-tarlatamab-in-small-cell-lung-cancer/ PharmaDeviceNews en 2026-10-25T04:43:04+00:00 AstraZeneca and Amgen report 58% lower death risk with IMFINZI and tarlatamab in small-cell lung cancer Amgen, AstraZeneca, CASPIAN, DeLLphi-304, DeLLphi-305, durvalumab, European Society for Medical Oncology, Imdelltra, Imfinzi, New England Journal of Medicine, tarlatamab https://pharmadevicenews.com/wp-content/uploads/2026/08/Lung-cancer-study-e1787082418957.webp https://pharmadevicenews.com/pfizers-new-vaccine-targets-25-pneumococcal-serotypes-but-can-it-outperform-prevnar-20/ PharmaDeviceNews en 2026-10-25T04:39:51+00:00 Pfizer’s new vaccine targets 25 pneumococcal serotypes, but can it outperform PREVNAR 20? Capvaxive, IDWeek 2026, Merck, PF-07872412, Pfizer, Prevnar 20, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/genmabs-rina-s-slashed-progression-risk-by-71-but-can-it-challenge-ovarian-cancer-treatment-standards/ PharmaDeviceNews en 2026-10-25T03:55:52+00:00 Genmab’s Rina-S slashed progression risk by 71%, but can it challenge ovarian cancer treatment standards? AbbVie, Corcept Therapeutics, ELAHERE, Genmab, Lifyorli, mirvetuximab soravtansine, ProfoundBio, RAINFOL-01, RAINFOL-02, Rina-S, Rinatabart Sesutecan, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/10/Ovarian-cancer-research-e1792867043247.webp https://pharmadevicenews.com/palleon-pharmaceuticals-reports-rapid-remissions-with-hlx79-e-602-in-phase-2-kidney-disease-trial/ PharmaDeviceNews en 2026-10-25T03:51:23+00:00 Palleon Pharmaceuticals reports rapid remissions with HLX79/E-602 in Phase 2 kidney disease trial American Society of Nephrology, Carolyn Bertozzi, efgitasialase alfa, HANLIKANG, HLX79/E-602, Palleon Pharmaceuticals, rituximab, Shanghai Henlius Biotech https://pharmadevicenews.com/wp-content/uploads/2026/07/Genentechs-Gazyva-gains-FDA-Priority-Review-after-Phase-III-MAJESTY-kidney-trial-e1784095258450.webp https://pharmadevicenews.com/vopimetostat-and-daraxonrasib-show-strong-tumor-responses-as-tango-therapeutics-targets-phase-3/ PharmaDeviceNews en 2026-10-24T19:13:18+00:00 Vopimetostat and daraxonrasib show strong tumor responses as Tango Therapeutics targets Phase 3 European Society for Medical Oncology, Pancreatic Cancer Action Network, Revolution Medicines, Tango Therapeutics, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/10/Pancreatic-Cancer-Research-e1792868623316.webp https://pharmadevicenews.com/rina-s-phase-3-success-brings-new-hope-for-platinum-resistant-ovarian-cancer-patients/ PharmaDeviceNews en 2026-10-24T18:38:38+00:00 Rina-S Phase 3 success brings new hope for platinum-resistant ovarian cancer patients Duke Cancer Institute, Genmab A/S, Gynecologic Oncology Group, Rina-S, Rinatabart Sesutecan, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/10/Ovarian-cancer-research-e1792867043247.webp https://pharmadevicenews.com/roche-and-ionis-report-43-1-proteinuria-reduction-with-sefaxersen-in-phase-3-iga-nephropathy-trial/ PharmaDeviceNews en 2026-10-24T07:07:09+00:00 Roche and Ionis report 43.1% proteinuria reduction with sefaxersen in Phase 3 IgA nephropathy trial American Society of Nephrology, AstraZeneca, Genentech, IMAgINATION, Ionis Pharmaceuticals, iptacopan, Roche Holding, sefaxersen, ULTOMIRIS, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/vertex-pharmaceuticals-reports-new-phase-3-rainier-data-for-povetacicept-in-iga-nephropathy/ PharmaDeviceNews en 2026-10-24T07:01:10+00:00 Vertex Pharmaceuticals reports new Phase 3 RAINIER data for povetacicept in IgA nephropathy American Society of Nephrology, New England Journal of Medicine, Otsuka Pharmaceutical, povetacicept, RAINIER, sibeprenlimab, United States Food and Drug Administration, Vertex Pharmaceuticals, VOYXACT https://pharmadevicenews.com/wp-content/uploads/2026/07/Otsukas-two-year-VOYXACT-data-could-redefine-IgA-nephropathy-treatment-e1782965591239.webp https://pharmadevicenews.com/what-does-gondolabios-childrens-tumor-foundation-partnership-mean-for-nf1-drug-research/ PharmaDeviceNews en 2026-10-24T04:40:54+00:00 What does GondolaBio’s Children’s Tumor Foundation partnership mean for NF1 drug research? Annette Bakker, BridgeBio Pharma, Charlie Ge, Children's Tumor Foundation, Cybele Gouverneur, GondolaBio, neurofibromatosis type 1, NF1, selumetinib https://pharmadevicenews.com/wp-content/uploads/2026/04/Whitehawk-Therapeutics-expands-its-oncology-narrative-with-AACR-2026-data-across-three-ADC-candidates-e1776662901880.webp https://pharmadevicenews.com/summit-therapeutics-partners-with-lunit-to-study-ai-tumor-biomarkers-for-ivonescimab/ PharmaDeviceNews en 2026-10-24T04:36:10+00:00 Summit Therapeutics partners with Lunit to study AI tumor biomarkers for ivonescimab Akeso, HARMONi, HARMONi-3, HARMONi-7, Ivonescimab, Lunit, Lunit SCOPE IO, SMT112, Summit Therapeutics, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/05/Antengenes-CLINCH-3-clearance-puts-ATG-022-into-the-pivotal-gastric-cancer-race-e1779981022130.webp https://pharmadevicenews.com/travere-therapeutics-filspari-shows-sustained-biomarker-reductions-in-phase-3-protect-study/ PharmaDeviceNews en 2026-10-24T04:31:56+00:00 Travere Therapeutics FILSPARI shows sustained biomarker reductions in Phase 3 PROTECT study American Society of Nephrology, FILSPARI, PROTECT, sparsentan, Travere Therapeutics https://pharmadevicenews.com/wp-content/uploads/2026/06/Mercks-Keytruda-and-Welireg-approval-reshapes-adjuvant-kidney-cancer-competition-e1781439990456.webp https://pharmadevicenews.com/genialis-ai-predicts-cancer-treatment-response-in-small-clinical-trials-using-biology-first-models/ PharmaDeviceNews en 2026-10-24T04:02:35+00:00 Genialis AI predicts cancer treatment response in small clinical trials using biology-first models European Society for Medical Oncology, Genialis, Genialis Supermodel, GitLab, KRAS G12C, pembrolizumab, Sid Sijbrandij, sotorasib https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Clinical-Trials.webp https://pharmadevicenews.com/advancell-reports-80-psa-response-with-advc001-in-updated-phase-1-prostate-cancer-study/ PharmaDeviceNews en 2026-10-24T03:57:34+00:00 AdvanCell reports 80% PSA response with ADVC001 in updated Phase 1 prostate cancer study AdvanCell, ADVC001, European Society for Medical Oncology, Lead-212, Novartis, Pluvicto, Princess Alexandra Hospital, prostate-specific membrane antigen, South Australian immunoGENomics Cancer Institute, TheraPb https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Cancer-generic.webp